Wuhan Hvsen Biotechnology Co Ltd (300871) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥59.06 Million ≈ $8.64 Million USD) by net assets (CN¥2.12 Billion ≈ $309.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300871 market cap overview for the company's overall valuation and market capitalisation.
Wuhan Hvsen Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Explore Wuhan Hvsen Biotechnology Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Sea Star Technology
SHE:002137
|
0.031x |
|
Stx Engine
KO:077970
|
0.003x |
|
YoungPoong
KO:000670
|
0.076x |
|
Rogers Sugar Inc.
TO:RSI
|
0.099x |
|
Dexterra Group Inc
TO:DXT
|
0.148x |
|
Contrel Technology Co Ltd
TWO:8064
|
0.088x |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
-0.191x |
|
BCI Minerals Limited
F:BC3
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. View Wuhan Hvsen Biotechnology Co Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.19 Billion ≈ $319.94 Million |
CN¥238.45 Million ≈ $34.89 Million |
0.109x | +267.07% |
| 2024-12-31 | CN¥1.47 Billion ≈ $214.41 Million |
CN¥43.53 Million ≈ $6.37 Million |
0.030x | -51.74% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.86 Million |
CN¥92.92 Million ≈ $13.60 Million |
0.062x | -1.84% |
| 2022-12-31 | CN¥1.54 Billion ≈ $225.56 Million |
CN¥96.68 Million ≈ $14.15 Million |
0.063x | -34.79% |
| 2021-12-31 | CN¥1.62 Billion ≈ $236.89 Million |
CN¥155.72 Million ≈ $22.79 Million |
0.096x | +174.38% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.81 Million |
CN¥48.35 Million ≈ $7.08 Million |
0.035x | -87.40% |
| 2019-12-31 | CN¥378.28 Million ≈ $55.35 Million |
CN¥105.24 Million ≈ $15.40 Million |
0.278x | +327.97% |
| 2018-12-31 | CN¥324.52 Million ≈ $47.49 Million |
CN¥21.10 Million ≈ $3.09 Million |
0.065x | -82.00% |
| 2017-12-31 | CN¥223.11 Million ≈ $32.65 Million |
CN¥80.56 Million ≈ $11.79 Million |
0.361x | -6.91% |
| 2016-12-31 | CN¥154.70 Million ≈ $22.64 Million |
CN¥60.00 Million ≈ $8.78 Million |
0.388x | -- |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildi… Read more